about
Neuron-restrictive silencer factor-mediated downregulation of μ-opioid receptor contributes to the reduced morphine analgesia in bone cancer pain.Mas-related G-protein-coupled receptor c agonist bovine adrenal medulla 8-22 attenuates bone cancer pain in mice.Morphine modulates doxorubicin uptake and improves efficacy of chemotherapy in an intracranial xenograft model of human glioblastomaPainful boney metastases.Spinal activation of delta opioid receptors alleviates cancer-related bone pain.A Prospective, Non-interventional Study of Assessment and Treatment Adequacy of Pain in the Emergency Department of a Tertiary Care Cancer Hospital.Morphine versus methylprednisolone or aminophylline for relieving dyspnea in patients with advanced cancer in China: a retrospective study.Alternative routes to oral opioid administration in palliative care: a review and clinical summary.Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.Options for Treating Pain in Cancer Patients with Dysphagia.The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.Opioid use and effectiveness of its prescription at discharge in an acute pain relief and palliative care unit.Pain in blood cancers.Improving the quality of life of terminally ill oncological patients: the example of palliative care at Hospice Villa Speranza.Direct effects of morphine but not of fentanyl-type opioids on human 5-HT3A receptors in outside-out patch-clamp studies.Continuous morphine infusion for end-stage lung cancer patients.Adult cancer pain.The Regulatory Mechanisms and Therapeutic Potential of MicroRNAs: From Chronic Pain to Morphine Tolerance.
P2860
Q33595867-CA9C8C5F-6E72-4655-B6A6-8B19608980C8Q36492651-F29E1B43-1E9C-4C4D-8031-3DF28E9D6CD9Q36853871-258067A5-CEA9-4FC8-AF0F-D335B66BBBE9Q37011060-177A91DE-638A-444C-828B-10C4F496E36AQ37360319-0C42EF57-4C7B-45EB-A755-CFD5748BBA84Q37368989-1F567C1A-3B57-4690-ABCF-02DA8F9036D7Q37405245-02DE2575-CFF3-42DA-B961-A8E7513E8C7DQ38226298-690D65DE-B84D-4A76-8A63-6E9319C00D9AQ38264067-AD4C9C75-4C4F-4D3A-A608-5015C7C20CC2Q39155742-4BEE987C-E4D3-4826-9A8E-57A088F3BCEAQ39229449-BFEC27BA-4529-44A9-A975-F6BAD0DB1D1AQ39232586-B3D27B57-5BB6-4B2C-A8AD-2F2A057EEB2BQ39251577-08D1AD66-4E73-4DE9-AF1D-D8F5B456EFD2Q39411189-A626A02F-B552-4074-922F-840799C887C6Q40174770-AA8E0F80-D3EE-48E8-AC1C-81AD03D7FC77Q43161564-548F6201-CF92-41BC-934B-3B92AD0F07F1Q44426953-8C64C9D9-903C-42CE-818E-F3429EE05E57Q55315782-5C879BBE-948A-4E54-BF0F-B1A698BA764A
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intravenous morphine for management of cancer pain.
@en
Intravenous morphine for management of cancer pain.
@nl
type
label
Intravenous morphine for management of cancer pain.
@en
Intravenous morphine for management of cancer pain.
@nl
prefLabel
Intravenous morphine for management of cancer pain.
@en
Intravenous morphine for management of cancer pain.
@nl
P1433
P1476
Intravenous morphine for management of cancer pain.
@en
P304
P356
10.1016/S1470-2045(09)70350-X
P577
2010-05-01T00:00:00Z